T
ALXN

TOBAM’s Alexion Pharmaceuticals ALXN Stock Holding History

TOBAM’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-718
Closed -$112K – 449
2020
Q4 		$112K Hold
718
– – 0.01% 238
2020
Q3 		$82K Buy
+718
New +$77.5K ﹤0.01% 243
2018
Q2 		– Sell
-117,676
Closed -$13.1M – 175
2018
Q1 		$13.1M Sell
117,676
-216,282
-65% -$25.9M 0.54% 65
2017
Q4 		$39.9M Sell
333,958
-32,892
-9% -$4.01M 1.73% 14
2017
Q3 		$51.5M Sell
366,850
-53,965
-13% -$7.33M 1.94% 10
2017
Q2 		$51.2M Buy
420,815
+147,028
+54% +$17.1M 1.91% 14
2017
Q1 		$33.2M Buy
273,787
+199,294
+268% +$25.7M 1.28% 32
2016
Q4 		$9.11M Buy
74,493
+59,692
+403% +$7.3M 0.37% 64
2016
Q3 		$1.81M Buy
+14,801
New +$1.91M 0.07% 101

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $7.94B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $14.1B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $4.65B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return